MGH FTD Unit Launches From Care to Cure Podcast
The MGH FTD Unit is excited to share that we are launching From Care to Cure, a podcast exploring care for a life lived with frontotemporal disorders, Alzheimer’s disease and related [...]
MGH FTD Unit celebrates FDA approval of donanemab
Today the U.S. Food and Drug Administration approved donanemab for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild [...]
Noche de Cine – Movie Night and Discussion about Early-Onset Dementia
Thursday, April 25, 2024
5:30 - 7:30 PM EST
Dawn of a new era: Lecanemab infusions begin at MGH
Today the first MGH patients received lecanemab infusions for early-stage Alzheimer’s disease. We have been working diligently with our colleagues at the Brigham to develop uniform procedures for [...]
MGH FTD Unit praises change in Medicare coverage of amyloid PET scans
Medicare lifted the requirement that FDA-approved amyloid PET scans would only be covered if they were performed as part of a clinical trial, now enabling them to be ordered and interpreted in [...]
MGH FTD Unit applauds FDA approval of lecanemab
The U.S. Food and Drug Administration converted Leqembi (lecanemab), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a [...]
Alzheimer’s Association Welcomes FDA Approval of Aducanumab
On behalf of those impacted by Alzheimer’s disease, the Alzheimer’s Association enthusiastically welcomes today’s historic FDA approval of aducanumab (Biogen/Eisai) for the treatment of [...]